OSLO,
Norway, Sept. 8, 2022 /PRNewswire/ -- Photocure
ASA, The Bladder Cancer Company, is delighted to continue
supporting the global launch activities of the new and improved
Blue Light Cystoscopy (BLC®) system to be used with
Photocure's product Hexvix® for the detection of
bladder cancer. In Europe, the
photodynamic diagnostics (PDD) system based on the new light source
POWER LED SAPHIRA™ from KARL STORZ was featured for the first time
in an E-Masterclass Webinar, hosted by both companies on
September 6. This event was
accompanied by the leading experts in Urology in the field of
Bladder Cancer.
Together with the experts from KARL STORZ and Photocure, Prof.
Arnulf Stenzl, Prof. Lukas Lusuardi,
Dr. Param Mariappan and Prof. Morgan
Rouprêt showcased the new next-generation Blue Light system
to the E-Masterclass participants. Over 400 registered delegates
could see how the "IMAGE1 S™ SAPHIRA™" system improves
visualization of bladder cancer via practical case studies.
Manufactured and commercialized by KARL STORZ, the new Blue Light
system is the next generation, improving the Blue Light experience
and providing next-level visualization.
"In the last months, I have had the opportunity to use the
new Saphira light source, which really ameliorates the quality of
the procedure significantly", said Prof. Lukas Lusuardi,
Professor of the Department of Urology at Paracelsus Medical
University (PMU) Hospital Salzburg,
Austria. "The quality of vision was exceptional –
even in white light. With PDD and the new POWER LED Saphira, I was
very comfortable to make the resection and TURBT under blue light,
which was not the case before, I have to say. So especially with
the bipolar resection, I feel quite comfortable to perform the
resection under the blue light, just to be sure in the best
possible way", added Prof. Morgan Rouprêt, full Professor
(academic position) at APHP Sorbonne University, in the Academic
Urology Department of the Pitié-Salpétrière Hospital, in
Paris, France.
"We are proud to be part of the ongoing launch of this
exciting new high-definition system in Europe," commented Dr. Susanne Strauss, Vice President and General
Manager, Europe at Photocure.
"Photodynamic diagnostics (PDD) is an important cornerstone of
accurate diagnosis and treatment of bladder cancer. This
advancement in KARL STORZ's equipment will provide a better Blue
Light experience for our customers, as the overwhelmingly positive
feedback from the e-masterclass clearly shows," Susanne Strauss concluded.
"PDD started in Germany,
with the full commitment of KARL STORZ, and so it is a pleasure for
us to introduce the new IMAGE1 S™ SAPHIRA™ system in
the E-Masterclass on NMIBC with PDD," said Paolo Cantù,
Director Urology Global Marketing at KARL STORZ. "The new light
source POWER LED SAPHIRA™ will allow us to serve
the needs of our healthcare partners, providing high image quality
in white light as well as in blue light for the detection and
treatment of bladder cancer. Together with the Photocure team we
now make high-quality BLC available to more patients
worldwide".
Note to editors
Hexvix®/Cysview® and BLC® are
registered trademarks of Photocure ASA. Saphira™ is a registered
trademark of KARL STORZ Endoscopy.
This press release may contain product details and information
which are not valid, or a product that is not accessible, in your
country. Please be aware that Photocure does not take any
responsibility for accessing such information, which may not comply
with any legal process, regulation, registration, or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer
worldwide – the 5th most common in men – with
1 720 000 prevalent cases (5-year prevalence
rate)1a, 573 000 new cases and more than
200 000 deaths annually in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate, with up to 61% in
year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all cases and include the
subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3, and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b)
incidence/mortality by population. Available at:
https://gco.iarc.fr/today, accessed [January
2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5):
639-657
3 Sievert KD et al. World J Urol
2009;27:295–300
4 Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder, making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview,
compared to standard white light cystoscopy alone, improves the
detection of tumors and leads to more complete resection, fewer
residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly
in the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Chile, Australia, New
Zealand and Israel. Please
refer to https://photocure.com/partners/our-partners for further
information on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway, and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
About KARL STORZ
The medical technology company KARL STORZ was founded in 1945 in
Tuttlingen, Germany, and is an
international leader in the world of endoscopy. Now in its third
generation, the family-owned company employs 8,300 people in 40
countries worldwide. The company portfolio includes more than
15,000 products for human and veterinary medicine. KARL STORZ
stands for visionary design, precision craftsmanship and clinical
effectiveness. Sales for the fiscal year 2021 amounted to
1.97 billion euros. Production sites
are located in Germany, the
USA, Switzerland and Estonia. Please find more information at:
www.karlstorz.com
CONTACT:
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/photocure/r/bladder-cancer-technology--new-karl-storz-blue-light-cystoscopy-system-featured-during-e-masterclass,c3627628
The following files are available for download:
|
https://mb.cision.com/Main/17498/3627628/1624330.pdf
|
KarlStorz-Photocure_E-masterclass_8Sept2022
|